Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CHTP's Cash to Debt is ranked higher than
94% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CHTP: No Debt )
CHTP' s 10-Year Cash to Debt Range
Min: 2.39   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CHTP's Interest Coverage is ranked higher than
83% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CHTP: No Debt )
CHTP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 68.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -73.09
CHTP's ROE (%) is ranked higher than
63% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. CHTP: -73.09 )
CHTP' s 10-Year ROE (%) Range
Min: -155.41   Max: -41.83
Current: -73.09

-155.41
-41.83
ROA (%) -65.60
CHTP's ROA (%) is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. CHTP: -65.60 )
CHTP' s 10-Year ROA (%) Range
Min: -107.24   Max: -38.02
Current: -65.6

-107.24
-38.02
ROC (Joel Greenblatt) (%) -29327.64
CHTP's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. CHTP: -29327.64 )
CHTP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -44344.19   Max: -14358.47
Current: -29327.64

-44344.19
-14358.47
EBITDA Growth (3Y)(%) -35.90
CHTP's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CHTP: -35.90 )
CHTP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 230.2
Current: -35.9

0
230.2
EPS Growth (3Y)(%) -35.90
CHTP's EPS Growth (3Y)(%) is ranked higher than
60% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CHTP: -35.90 )
CHTP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 220.8
Current: -35.9

0
220.8
» CHTP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CHTP Guru Trades in Q3 2013

Jim Simons 225,695 sh (+2071.4%)
Chuck Royce 560,000 sh (-11.11%)
» More
Q4 2013

CHTP Guru Trades in Q4 2013

Paul Tudor Jones 20,895 sh (New)
Jim Simons 716,494 sh (+217.46%)
Chuck Royce 120,000 sh (-78.57%)
» More
Q1 2014

CHTP Guru Trades in Q1 2014

Chuck Royce Sold Out
Paul Tudor Jones 20,365 sh (-2.54%)
Jim Simons 33,306 sh (-95.35%)
» More
Q2 2014

CHTP Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CHTP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-09-30 Sold Out 0.0025%$3.56 - $5.89 $ 6.5242%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.17
CHTP's P/B is ranked higher than
62% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. CHTP: 14.17 )
CHTP' s 10-Year P/B Range
Min: 0   Max: 22
Current: 14.17

0
22
EV-to-EBIT -23.20
CHTP's EV-to-EBIT is ranked higher than
83% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CHTP: -23.20 )
CHTP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -23.2

Current Ratio 9.65
CHTP's Current Ratio is ranked higher than
86% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CHTP: 9.65 )
CHTP' s 10-Year Current Ratio Range
Min: 1.51   Max: 14.47
Current: 9.65

1.51
14.47
Quick Ratio 9.65
CHTP's Quick Ratio is ranked higher than
87% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CHTP: 9.65 )
CHTP' s 10-Year Quick Ratio Range
Min: 1.51   Max: 14.47
Current: 9.65

1.51
14.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.52
CHTP's Price/Net Cash is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. CHTP: 15.52 )
CHTP' s 10-Year Price/Net Cash Range
Min: 2   Max: 24.38
Current: 15.52

2
24.38
Price/Net Current Asset Value 15.52
CHTP's Price/Net Current Asset Value is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. CHTP: 15.52 )
CHTP' s 10-Year Price/Net Current Asset Value Range
Min: 2   Max: 24.38
Current: 15.52

2
24.38
Price/Tangible Book 14.82
CHTP's Price/Tangible Book is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. CHTP: 14.82 )
CHTP' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 23.27
Current: 14.82

1.63
23.27
Earnings Yield (Greenblatt) -4.30
CHTP's Earnings Yield (Greenblatt) is ranked higher than
77% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CHTP: -4.30 )
CHTP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.3   Max: 0
Current: -4.3

-4.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3CH.Germany,
Chelsea Therapeutics International, Ltd., is a specialty pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products. The Company's currently licensed compounds target a variety of prevalent medical conditions; particularly rheumatoid arthritis, psoriasis, cancer, other immunological disorders, neurogenic orthostatic hypotension and other autonomic disorders. The Company is developing droxidopa, an orally active synthetic precursor of norepinephrine and its investigational product candidate, for the treatment of neurogenic orthostatic hypotension (NOH). It is currently focusing the majority of its drug development resources on two clinical stage development projects: droxidopa for symptomatic neurogenic orthostatic hypotension and other potential indications; and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis. Droxidopa, a synthetic amino acid, is converted by the body into norepinephrine and, as a prodrug of norepinephrine, provides replacement therapy for norepinephrine deficiency. Norepinephrine is both a hormone and a neurotransmitter. As a hormone, secreted by the adrenal gland, it works alongside epinephrine/adrenaline to give the body sudden energy in times of stress, known as the 'fight or flight' response. As a neurotransmitter, it passes nerve impulses from one neuron to the next. While norepinephrine, as a catecholamine does not penetrate the blood-brain barrier, droxidopa, as a neutral amino acid, is able to do so thus providing both a peripheral and central effect on circulating norepinephrine levels. The FDA and foreign regulatory agencies regulate many aspects of product development and marketing of its product candidates including research, development, manufacture, labeling, promotion, advertising, distribution, and marketing.
» More Articles for CHTP

Headlines

Articles On GuruFocus.com
Columbia Wanger Chucks Chelsea, Despite FDA Progress Apr 09 2013 
Chelsea Therapeutics International Ltd. (CHTP) CFO J Nick Riehle buys 3,000 Shares Nov 05 2010 
Chelsea Therapeutics International Ltd. (CHTP) CEO Simon Pedder buys 1,250 Shares Sep 07 2010 
Chelsea Therapeutics International Ltd. Reports Operating Results (10-Q) May 04 2010 
Chelsea Therapeutics International Ltd. (CHTP) CEO Simon Pedder buys 4,600 Shares Dec 21 2009 
Chelsea Therapeutics International Ltd. Reports Operating Results (10-Q) Nov 02 2009 
Chelsea Therapeutics International Ltd. Reports Operating Results (10-Q) Aug 05 2009 
Chelsea Therapeutics International Ltd. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 8-K, Notice of Delisting or Failure to... Jun 24 2014
Lundbeck Delivers Some Data-Driven Upside Jun 20 2014
Chelsea Therapeutics announces expiration of HSR waiting period Jun 06 2014
The Law Office of Robbins Arroyo LLP Announces Class Action Lawsuit Against Chelsea Therapeutics... Jun 02 2014
Chelsea Therapeutics Deal Terms: Be Careful Jun 02 2014
Chelsea Therapeutics - Going Private Transaction Provides Significant Upside May 29 2014
Chelsea Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP... May 21 2014
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Financials May 20 2014
Chelsea Therapeutics downgraded to Neutral from Buy at Roth Capital May 20 2014
Options with decreasing implied volatility: CHTP OLED GRPN RAX AEGR May 13 2014
Acquisition Chelsea Therapeutics International, Ltd by H. Lundbeck A/S May Not Be in Shareholders'... May 12 2014
Options with decreasing implied volatility: CHTP NSR HZNP GMCR OLED May 12 2014
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 8-K, Other Events May 12 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Chelsea Therapeutics... May 09 2014
Harwood Feffer LLP Announces Investigation of Chelsea Therapeutics International, Ltd. May 09 2014
Lifshitz & Miller Law Firm Announces Investigation of Chelsea Therapeutics International Ltd., KBR,... May 09 2014
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. Files SEC form 10-Q, Quarterly Report May 09 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Chelsea Therapeutics International,... May 09 2014
Lundbeck Starting Slow, But Still Looking For The Big Finish May 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK